Arbutus Biopharma (ABUS) Misses Q1 EPS by 3c

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.13), $0.03 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $1.76 million versus the consensus estimate of $1.77 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Frequency Electronics secures $10 million credit facility with JPMorgan